WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
BIOMEDICAN | December 03, 2020
BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances.
Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...
Mission Bio | March 30, 2022
Mission Bio, Inc., a pioneer in high-throughput single-cell DNA and multi-omics research, announced the commercial availability of the Tapestri Solution for Solid Tumor Research. On the Tapestri Platform, this new end-to-end single-cell DNA sequencing process comprises a nuclei isolation prep technique, pre-designed research panels for breast cancer and glioblastoma multiforme, and an enhanced single-cell copy number variation (CNV) bioinformatic analysis tool. Mission Bio currently covers solid...
CEBINA | July 13, 2020
CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...
ArgoBio and Oncode Institute | February 08, 2022
ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of ...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE